Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS G12C -Mutated NSCLC Treated With Sotorasib.
Sophie M ErnstRonald van MarionPeggy N AtmodimedjoEvert de JongeRon H J MathijssenMarthe S PaatsPeter de BruijnStijn L KoolenJan H von der ThüsenJoachim G J V AertsRon H N van SchaikHendrikus J DubbinkAnne-Marie C DingemansPublished in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2024)
ctDNA as a marker for poor prognosis and on-treatment ctDNA clearance as a marker for treatment response. We identified KRAS amplifications as a potential recurring resistance mechanism to sotorasib. Identifying patients with superior prognosis could aid in optimizing time of treatment initiation, and identifying patients at risk of early progression could allow for earlier treatment decisions.